Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending January 30, 2006. The report serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility, or Connected Persons regarding the company's Ordinary Shares.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is strictly a regulatory notification of share transactions and does not contain financial performance data.
Material Changes
The filing details a specific transaction on January 26, 2006:
- Abacus (GSK) Trustees Limited, acting as trustee for the GlaxoSmithKline Employee Trust ("GSK Trust"), transferred 18,445 Ordinary Shares to participants in the SmithKline Beecham Employee Share Option Plan 1991.
- The Company was advised of these transactions on January 27, 2006.
Management Commentary and Risks
The GSK Trust is identified as a discretionary trust where all current and former employees of GlaxoSmithKline plc and its subsidiaries are potential beneficiaries. The filing notes that three directors—Dr J-P Garnier, Dr T Yamada, and Mr J S Heslop—hold an interest in the shares held within the GSK Trust in the same capacity as other employees. No other risks, contingencies, or unusual items are disclosed in this text.
Investor Verification Points
- Verify the total number of shares held by the GSK Trust prior to and after the January 26, 2006 transfer.
- Confirm the specific number of shares allocated to each participant in the SmithKline Beecham Employee Share Option Plan 1991.
- Review the full Disclosure Rule 3.1.4R(1)(b) requirements to ensure complete compliance regarding the directors' interests.